Nuwellis to launch 24-hour Aquadex therapy circuit this fall

MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE), currently trading near its 52-week low with a market capitalization of $4.45 million, plans to introduce a new 24-hour circuit for its Aquadex therapy in the United States this fall, according to a company press release issued Thursday. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt, despite challenging market conditions.

The new circuit is designed specifically for single-day outpatient sessions and will complement Nuwellis’ existing 72-hour option, which is typically used for multi-day therapy or inpatient care. The company states this addition will help hospitals align supply with treatment settings while maintaining consistent therapy delivery. With annual revenue of $8.32 million and a gross profit margin of 62.35%, Nuwellis demonstrates strong operational efficiency in its medical device business.

"Hospital-based outpatient Aquadex therapy is growing as a reliable option for patients who need fluid removal without a hospital admission. The 24-hour circuit supports that model with a straightforward single-visit pathway," said John Erb, Chairman of the Board and Chief Executive Officer of Nuwellis.

The company indicates the new circuit is intended to support hospitals developing outpatient programs for scheduled fluid removal procedures. For healthcare providers, the shorter-duration circuit aims to facilitate more efficient clinic operations and capacity planning.

Nuwellis also mentioned it provides resources for hospital-based outpatient sites, including implementation guidance and staff education to support Aquadex therapy in ambulatory settings.

The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kg or more whose fluid overload does not respond to medical management, including diuretics. All treatments must be administered by healthcare providers in clinical settings under physician prescription.

Nuwellis is headquartered in Minneapolis and trades on the Nasdaq under the ticker NUWE. InvestingPro analysis indicates the stock is currently undervalued, with 15+ additional ProTips available to subscribers. For comprehensive insights into Nuwellis and 1,400+ other stocks, access the detailed Pro Research Report through InvestingPro.

In other recent news, Nuwellis, Inc. reported a challenging second quarter of 2025, experiencing a 21% decline in total revenue, bringing in CAD $1.7 million and facing a significant net loss. Despite these financial hurdles, the company is actively pursuing strategic initiatives to bolster its market presence. In a move to expand its product offerings, Nuwellis announced it has received FDA 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter, specifically a 15 cm insertable length option. This new size complements the existing 11 cm catheter, both designed for ultrafiltration therapy.

Furthermore, Nuwellis has entered into a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli medical device company. The acquisition aims to enhance Nuwellis’s technology platform by incorporating Rendiatech’s real-time urine flow and acute kidney injury monitoring technologies. Rendiatech’s Clarity RMS, an FDA-cleared system, and its upcoming Clarity Prime system are expected to advance Nuwellis’s capabilities in renal health monitoring. These developments indicate Nuwellis’s commitment to broadening its technological scope despite recent financial setbacks.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.